JAMA Neurology Examines Rituxan

Wednesday, January 24, 2018

This study, recently published in the journal JAMA Neurology, examined the use of Rituximab as a first-line MS treatment in Sweden. Rituximab is already extensively used in Sweden but this study showed the improved efficacy and safety of using Rituximab as a first MS treatment as compared to other MS drugs. However, as Rituximab is not FDA-approved in the United States for MS, its use early in MS is limited due to restrictions by insurance companies.


News Archive


Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy


Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.